Introduction: Extracorporeal membrane oxygenation (ECMO) is considered a rescue therapy in severe cases of acute cardiac and or respiratory failure.
Introduction
Acute respiratory distress syndrome (ARDS) is a disease affecting the lungs secondary to primary pulmonary or extrapulmonary causes [1] . It was first described by Ashbaugh and colleagues in 1967 [2] . The disease is characterized as an acute diffuse inflammatory lung injury leading to increased pulmonary vascular permeability and lung weight and loss of aerated lung tissue [1] . Alveolar filling affects proper oxygenation in addition to carbon dioxide removal in severe forms [3] . Based on the degree of hypoxemia, ARDS was categorized with correlation to mortality (Table 1 ) [3] . Severe ARDS characterized by Pa 2 /FiO 2 <100 is a challenging condition in the medical field especially to critical care physicians. Many ventilatory and non ventilatory strategies were studied and applied in the last decade that resulted in reducing mortality [4] ; this was mainly achieved through changing mechanical ventilation strategy that resulted in decreasing ventilator induced lung injury (VILI) [5, 6] . However despite these strategies, mortality is still high in severe ARDS [3] .
Extracorporeal membrane oxygenation (ECMO) is not a newly developed technique. The main aim of ECMO development was trying to maintain tissue oxygenation through bypassing the lungs when other strategies fail. The theory was to develop a membrane lung that can withstand hydrostatic pressure and is permeable to gas exchange. The first developed silicon rubber membrane was by Kemmermeyer in 1957 [7] then in 1968, Kolobow and Zapol developed the first membrane oxygenator that can withstand prolonged operation [8] . The theory although very attractive and logical has faced many challenges over the years. The first challenge was the mode of bypass in respiratory failure which changed from Veno-Arterial (VA) to Veno-venous (VV) sparing a lot of potentially life threatening complications, the second challenge was the associated coagulopathy [9, 10] as coagulation system activation occurs immediately after contact with the non-biological surface of ECMO unit leading to tissue factor activation [11] [12] [13] . Platelet adhesion and activation occurs upon exposure to the circuit resulting in thrombocytopenia and thrombasthenia [14, 15] . Bleeding occurred secondary to massive anticoagulation use to prevent thrombosis of the older huge membrane lungs with consequent need for massive blood transfusion [16] . The third was hemolysis created by prolonged use of the roller pump which dramatically improved after the development of the centrifugal pump achieving higher flow with less hemolysis over time [17, 18] , the fourth was the shift from thrombogenic and inflammatory-inducing circuits to heparin coated and biocompatible circuits that need less anticoagulation (with consequent less bleeding) [19] [20] [21] , and the fifth, was the miniaturizing of ECMO consoles that allowed ECMO retrieval [22] . Perhaps the most important challenge was the lack of randomized control trials to show superiority of ECMO over standard therapy. This was first established in neonates in 1996 by demonstrating the beneficial role of ECMO in neonatal respiratory distress syndrome [23] . In adults the proof of concept needed many years till finally the publishing of CESAR trial in 2009 showing significant survival benefit in severe ARDS patients transferred to an ECMO center when compared to receiving standard therapy in their Intensive care units [24] .
The H1N1 epidemic in 2009 resulted in the expansion of ECMO use in developed countries. According to the ELSO registry the use of ECMO has steadily increased with obvious growth in years 2009 through 2011 [25] . Lung pathology in proven H1N1 patients was mainly diffuse alveolar damage, with two other pathology patterns of necrotizing bronchiolitis and extensive pulmonary hemorrhage [26] . There were three published registries, one in UK [27] , a second in New Zealand-Australia [28] and a third in France [29] . All these recent publications have suggested a potential survival benefit with ECMO use; however, none of them achieved the solid proof of concept about the value of ECMO in ARDS. The currently ongoing EOLIA randomized multicenter trial may answer this question [30] .
VILI in ARDS patients has been described by several authors and demonstrated in experimental studies [31, 32] . Further studies established the pivotal role of high volume lung ventilation and importance of the level of plateau pressure in the development of VILI [33, 34] . However, in severe cases the physicians have no choice but to use high PEEP and recruitment maneuvers to maintain oxygenation [5, 35, 36] with subsequent potentially deleterious effects on the lungs and uncertain benefit, especially with low recruitment potentials in addition to hemodynamic instability [35] . In severe cases the use of recommended low tidal volumes may result in hypercapnia with consequent pulmonary hypertension and the potential to develop acute cor-pulmonale leading to high mortality rates [37, 38] . The use of complete sedation and paralysis has been demonstrated to lead to diaphragmatic myopathy and respiratory muscle weakness [39, 40] .
The concept of using ECMO to allow ultra-protective ventilation or lung rest may lead to the shortening of ventilation and better healing of the lungs (but this remains to be proved). Bypassing mechanical ventilation in these cases with awake ECMO may be a target in the near future [41, 42] .
ECMO was recently introduced to the Middle East especially the gulf countries. Introduction of ECMO to Egypt was quite challenging with economic obstacles and lack of trained personnel in addition to the lack of convincing data.
Patients and methods
This study included all patients connected to ECMO from January 2014 till September 2015. The initial ECMO set up was in a single room in the department with air fluidized bed.
Upon arrival to our center all patients were subjected to detailed history of comorbidities, current illness including onset, duration, progression, investigations and treatments received. Murray lung injury score (LIS) for all patients was calculated using four parameters: [43] number of quadrants with consolidation in chest X-ray, PaO 2 /FiO 2 in mmHg, Positive end expiratory pressure in cm H 2 O, and Compliance in ml/cm H 2 O.
The score range from 1 to 4, and score above 3 represented severe ARDS with expected high mortality.
The Respiratory Extracorporeal Membrane Oxygenation Survival Prediction (RESP) score for all respiratory patients to determine the probability of survival on ECMO, is calculated on line in the website www.respscore.com [44] (Table 1) . The procedure and technique with potential complications were explained to the patients' guardians and an informed witnessed consent was obtained from the first degree relative before the initiation of therapy.
VV ECMO indications
Patients were considered for VV ECMO based on the criteria of ELSO organization; Refractory hypoxemia despite lung protective strategy according to ARDS rent protocol, severe respiratory academia with pH <7.25, and Murray lung injury score 3-4.
Exclusion criteria
Respiratory patients not fulfilling the indications are: Patients who are brain dead or didn't recover neurologically after the history of cardiopulmonary arrest, patients with terminal malignancy, patients with marked hemodynamic instability (septic shock) and multi-organ failure, patients older than 65 years, patients with prolonged mechanical ventilation >14 days, and patient relatives refusing ECMO treatment.
Cannulation

VV ECMO cases
All patients were cannulated percutaneously, using standard Seldinger technique Maquet Venous and arterial cannulae were used in 11 patients and Medtronic cannulae were used in 2 patients. All cannulae positions were confirmed by Echo after implantation and by bedside chest X-ray. Positions were modified according to the chest X-ray's presence of abnormal position or hemodynamically significant recirculation.
Femoro-jugular approach was attempted initially in 9 patients and was successful in 7 patients. One patient had Femoro-subclavian. Two patients had femoro-femoral.
VA ECMO cases
All patients were cannulated percutaneously, using standard Seldinger technique Maquet Venous and arterial cannulae were used in both patients. Cannulation was done in the cath-lab under image guidance, drainage cannula from femoral vein and arterial cannula in the femoral artery.
Consoles
We have the centrifugal pump systems including the polymethylpentene membrane from Maquet. The two available consoles were Cardiohelp and Rotaflow. The flow that can be achieved is 7 l/minute for the Cardiohelp and 8 l/m for the Rotaflow. The Cardiohelp is more compact and suitable for patient transportation. The pump and oxygenator are unified in the Cardiohelp and separate in the Rotaflow. Both consoles allow monitoring of flow and rounds per minute. Both have bubble detectors as well. The Cardiohelp console has a screen display that allows monitoring of SvO 2 , Hemoglobin, hematocrit, and pressures before, intra and after the oxygenator/pump unit. The Cardiohelp console allows storage of ECMO run data and data transfer in addition to different operation modality programs for VA, VV, PALP and rotaassist.
Mechanical ventilation
In VV ECMO cases
Ultraprotective lung strategy; pressure controlled ventilation with peak airway pressure set to 25 cm H 2 O and PEEP to 10 cm H 2 O. Patients were shifted to pressure support ventilation after the discontinuation of sedation.
In VA ECMO
Mechanical ventilation was adjusted to decrease the work of breathing and to achieve Right hand Oxygen saturation >90%.
Anticoagulation
A bolus of 80 IU/kg is given initially after cannulation is completed followed by Heparin intravenous infusion to keep aPTT 1.5 times the baseline usually 50-70 s. Bivalirudin is given if severe thrombocytopenia with a suspected HIT dose of 0.1 mg/kg/hour. Anticoagulation was discontinued in cases of major bleeding and reversal of heparin given only if the bleeding did not stop after the discontinuation of heparin. Other measures as fresh frozen plasma transfusion, vitamin K, tranexamic acid and activated factor VII were given as indicated and according to the laboratory patient data only in massive uncontrollable bleeding.
ECMO weaning
We initiated weaning when patients fulfilled the following criteria; 1 -improvement of lung mechanics which is marked by improving compliance and tidal volume, 2 -evident radiologic improvement in the form of starting lung aeration, 3 -need for less ECMO flow to achieve adequate oxygenation, 4 -withstands a weaning trial in the form of decreasing ECMO FiO 2 to 0.21 for 1 h with ventilator FiO 2 <0.6.
Weaning starts by keeping the ECMO flow at 3 l/m at least on ECMO FiO 2 of 0.21 for at least 12 h and ventilator FiO 2 <0.6, PEEP 10 cm H 2 O, and pressure support of 15 cm H 2 O.
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Decannulation was done after stopping heparin for 4 h and manual compression on the cannulation site for 30 min.
Laboratory investigations: for coagulation monitoring
Fibrinogen and aPTT Q 6 h NR daily.
Other procedures
Tracheostomy: performed percutaneously or surgically between day 10 and 14 after mechanical ventilation.
Results
A total of twelve patients received ECMO between January 2014 and June 2015.
The mean age was 35.9 years (range 13-65 years), 7 Males, with VV ECMO in 10 patients, and VA ECMO in 2 patients.
VV ECMO cases
Out of ten patients of VV ECMO, one had H1N1 pneumonia, One had advanced vasculitic lung, four had bacterial pneumonia, two traumatic lung contusions and one organophosphorus poisoning, and one undiagnosed etiology leading to severe ARDS (Fig. 1) .
Nine patients had ARDS complicating the original respiratory illness. The LIS ranged from 3 to 3.8 in those patients. One patient had refractory hypoxemia secondary to severe vasculitic lung disease. The PaO 2 /FiO 2 ratio ranged from 20 to 76 (Table 1) .
ECMO management and complications
Pump flow ranged from 2.6 to 6.5 L/min. Average support time was 12 days (range 2-24 days). B blockers were given in 5 patients, Ivabradine was given in 4 patients and packed red cell transfusions were given in all patients to improve oxygen delivery in cases needing high ECMO flow. Seven patients (63.3%) were successfully weaned off ECMO and survived to hospital discharge. Hospital length of stay ranged from 3 to 42 days, tracheostomy was done percutaneously in 5 patients and surgically in 3. Gastrointestinal bleeding occurred in 6 patients and was managed conservatively using intravenous proton pump inhibitors and temporary interruption of anticoagulation which ranged from 2 to 5 days. Ventilator associated pneumonia occurred in 7 patients. Neurologic complications developed in 1 patient which was small non hemorrhagic fronto-parietal infarction discovered due to prolonged disorientation after sedation vacation with lateralization on contralateral upper and lower limbs. This patient regained full consciousness level and motor power improved. Cardiac arrhythmias occurred in 3 patients all were atrial fibrillation two all of them were defibrillated and maintained on amiodarone, pneumothorax in 9 patients, and deep venous thrombosis in 2 patients ( Table 2 ).
VA ECMO cases
In the first VA ECMO case the patient was cannulated during CPR, femoro-femoral percutaneous approach. The patient showed no neurologic recovery and died after 24 h. The second VA ECMO case was a cardiogenic shock patient presenting with inferior STEMI coronary angiography showed severe multi-vessel disease attempted primary PCI failed and the patient was connected to ECMO and stabilized. CABG was done on ECMO after 24 h and the patient survived for 9 days with no myocardial recovery despite use of dobutamine and levosimendan. The course was complicated by occipital non hemorrhagic cerebral infarction and lower limb ischemia. The patient died due to refractory arrhythmias and asystole (Table 3 ).
Anticoagulation
Heparin intravenous infusion was used initially in all patients and changed to Bivalirudin in 2 VV ECMO patients due to possible HIT, with no bleeding or thrombotic complications related to Bivalirudin, and a significant rise in platelet count in next 48 h. introduction of ECMO carries many scientific medical and strategic goals. The Critical Care Department, Cairo University, founded in 1982 introduced the specialty to the medical community and took the lead in introducing many medical strategies and technologies related to this specialty since then. Introduction of ECMO through the department not only raised the enthusiasm in the whole country in specialty of Critical care but also added to the available technologies in the country.
Discussion
In the Critical care Department, Cairo University with limited resources and the help of donations the first successful ECMO unit was created in June 2013. In 24th January 2014 the first ARDS case was connected to VVECMO and successfully weaned on 13th February 2014.
The results of our center are benchmarked against the ELSO registry results with rather acceptable results in VV ECMO outcome with overall survival of 58% in adult respiratory ECMO cases [62] .
Proper selection of patients is still the main determinant of outcome. The patients who died represented a category already with calculated poor outcome as seen by their very low RESP scores.
Most of our respiratory cases fulfilled the criteria of severe ARDS with refractory hypoxemia that can benefit from ECMO support [1, 3, 24, 34] . Patients were ventilated according to ARDS net [45] protocol with low tidal volume 4-6 ml/kg/breath PEEP was increased incrementally while the patients were sedated and paralyzed [46] and following increase in FiO 2 reaching 100% inhaled oxygen, the peak inspiratory pressure was set to keep plateau pressure maximum of 35 cm H 2 O [45] . Steroids were tested in several studies [47] . All patients received steroids with a protocol similar to Meduri et al. with methylprednisolone 1 mg/kg/24 h with slight benefit as regards ventilation and length of stay [48] . Inhaled nitric oxide is one of the nonventilator strategies in severe ARDS however has doubtful survival benefit [6] and was not used in any of our patients due to unavailability in Egypt. Prone positioning showed in a recent publication a survival benefit when applied for prolonged periods of time and was tried in some cases.
Veno-venous femoro-jugular percutaneous [49, 50] cannulation approach was shown to be better than jugulo-femoral approach in these two studies and the distance of more than 15-20 cm between both cannulae favors less recirculation [50] . This was our initial approach tried in most patients unless there were anatomical barriers (one patient had bifurcating internal jugular vein another had massive surgical emphysema in the upper part of the body) or failed jugular route (one patient).
We followed the ultraprotective mechanical ventilation strategy demonstrated by Brodie [51] . Sedation and paralysis were continued to decrease respiratory work of breathing and avoid swing in pressures with spontaneous breathing; as recommended by the ACURASYS trial we used atracurium infusion and sometimes pancuronium boluses [46] . Pressure support ventilation was resumed as early as possible to avoid ventilator induced diaphragmatic dysfunction [34, 51] . Despite this strategy most of the patients developed barotrauma which reflects the very low compliance of the lungs [52] .
We sometimes used B-blockers or Ivabradine to decrease heart rate and cardiac output and improve oxygenation as a last step after increasing pump flow, control of fever and Packed red cell transfusions usually this resulted in decreasing the flow needed to achieve adequate oxygenation however we cannot deduce a conclusion from this small number of patients. Several studies have demonstrated the efficacy of this approach [53, 54] . Packed RBCS transfusion was used in several studies to improve oxygenation using lower pump flow rates in cases with relative hypoxia on ECMO decreasing hemolysis [18, 55, 56] .
We started weaning from ECMO without decreasing the flow below 3 l/m to avoid thrombosis of the circuit, our trial lasted for 24 h before decannulation and none of our patients needed resumption of support after decannulation. We experienced one oxygenator thrombosis during a planned weaning trial and the patient was decannulated [57] .
Bleeding complications on ECMO may be secondary to anticoagulation, heparin induced thrombotic thrombocytopenia or circuit induced fibrinolysis and consumption coagulopathy [58] , other causes may include acquired von Willebrand syndrome and dilution of coagulation factors [58, 59] .
Bleeding on ECMO is usually managed conservatively with PRBCs transfusion, platelet transfusion as needed and some reports showed benefits of giving tranexamic acid intravenously, surgical bleeding should receive surgical hemostatic measures [60] . With new heparin coated circuits it is possible to interrupt anticoagulation for hours or days [61] . In our patients we had life threatening pulmonary hemorrhage in a vasculitic lung patient who received; Protamine sulfate, tranexamic acid, fresh plasma, vitamin K, PRBCs and activated factor VII. Other patients needed just the discontinuation of heparin for variable periods (2-5 days) with concomitant need of PRBCs transfusion. None had circuit clotting during this period.
Secondary bacterial infections including ventilator associated pneumonia were the most common complications in our patients and were relatively higher than that demonstrated in other studies approaching 30-40% of cases [60] .
Conclusions
ECMO can be introduced in highly specialized tertiary centers in developing countries. Benchmarking against ELSO results may help continuous quality improvements in starting ECMO centers. 
